Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: the COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial - Mahaffey, KW; Granger, CB; Nicolau, JC (Circulation, 2003)
et al.